|
17 Oct 2019 |
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
|
|
17 Oct 2019 |
NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar Candidate in Phase I Clinical Trial
|
|
17 Oct 2019 |
Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|
|
17 Oct 2019 |
Bimekizumab Phase 3 Psoriasis Study Meets All Endpoints, Achieving Significantly Greater Efficacy Versus Placebo and Ustekinumab
|
|
17 Oct 2019 |
Ichnos Sciences Launches as New, Independent, Leading-Edge Biotech Dedicated to Outpacing Disease
|
|
17 Oct 2019 |
Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
|
|
16 Oct 2019 |
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
|
|
16 Oct 2019 |
Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
|
|
16 Oct 2019 |
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy Subject in a Phase I Study of HPG1860 for NASH
|
|
16 Oct 2019 |
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 1 Study of AP-101 for the Treatment of ALS
|
|
16 Oct 2019 |
Alexion to Acquire Achillion
|
|
16 Oct 2019 |
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically Suppressed Adults with HIV-1
|
|
16 Oct 2019 |
Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease
|
|
16 Oct 2019 |
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)
|
|
16 Oct 2019 |
Imbrium Therapeutics Announces First Patient Dosed in Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation
|
|
16 Oct 2019 |
Hope Biosciences Opens First Phase I/II Stem Cell Trial for Brain Injury Treatment
|
|
16 Oct 2019 |
Amphivena Initiates Solid Tumor Clinical Trial
|
|
16 Oct 2019 |
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
|
|
16 Oct 2019 |
miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
|
|
16 Oct 2019 |
Denovo Biopharma Receives FDA's Permission to Proceed with a Biomarker-Guided Phase 2b Clinical Trial with DB102 (Enzastaurin) In First-Line Treatment of Glioblastoma (GBM)
|
